Aprogen is a biopharmaceutical company that develops medicines using unique and innovative biological drug development technologies. Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid. Their main pipelines include novel drugs AP20, AP40, AP10, AP70, AP60, and biosimilars GS07, AP06, AP05, AP09[30^].
Aprogen
Category:
Venture
Main Business Area
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid
| Contact Details | 545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13215Tel : +82-31-625-4045 |
|---|
